Show simple item record

dc.contributor.authorSrivastava, Siddharth
dc.contributor.authorLove-Nichols, Jamie A.
dc.contributor.authorDies, Kira A.
dc.contributor.authorLedbetter, David H.
dc.contributor.authorMartin, Christa L.
dc.contributor.authorChung, Wendy K.
dc.contributor.authorFirth, Helen V.
dc.contributor.authorFrazier, Thomas
dc.contributor.authorHansen, Robin L.
dc.contributor.authorProck, Lisa
dc.contributor.authorBrunner, Han
dc.contributor.authorHoang, Ny
dc.contributor.authorScherer, Stephen W.
dc.contributor.authorSahin, Mustafa
dc.contributor.authorMiller, David T.
dc.contributor.author
dc.date.accessioned2020-09-25T16:20:22Z
dc.date.available2020-09-25T16:20:22Z
dc.date.issued2019-06-11
dc.date.submitted2019-02-20
dc.identifier.issn1098-3600
dc.identifier.others41436-019-0554-6
dc.identifier.other554
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/310729
dc.description.abstractAbstract: Purpose: For neurodevelopmental disorders (NDDs), etiological evaluation can be a diagnostic odyssey involving numerous genetic tests, underscoring the need to develop a streamlined algorithm maximizing molecular diagnostic yield for this clinical indication. Our objective was to compare the yield of exome sequencing (ES) with that of chromosomal microarray (CMA), the current first-tier test for NDDs. Methods: We performed a PubMed scoping review and meta-analysis investigating the diagnostic yield of ES for NDDs as the basis of a consensus development conference. We defined NDD as global developmental delay, intellectual disability, and/or autism spectrum disorder. The consensus development conference included input from genetics professionals, pediatric neurologists, and developmental behavioral pediatricians. Results: After applying strict inclusion/exclusion criteria, we identified 30 articles with data on molecular diagnostic yield in individuals with isolated NDD, or NDD plus associated conditions (such as Rett-like features). Yield of ES was 36% overall, 31% for isolated NDD, and 53% for the NDD plus associated conditions. ES yield for NDDs is markedly greater than previous studies of CMA (15–20%). Conclusion: Our review demonstrates that ES consistently outperforms CMA for evaluation of unexplained NDDs. We propose a diagnostic algorithm placing ES at the beginning of the evaluation of unexplained NDDs.
dc.languageen
dc.publisherNature Publishing Group US
dc.subjectSystematic Review
dc.subjectsystematic-review
dc.subjectautism
dc.subjectconsensus development conference
dc.subjectdiagnostic yield
dc.subjectgenetic testing
dc.subjectintellectual disability
dc.titleMeta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders
dc.typeArticle
dc.date.updated2020-09-25T16:20:22Z
prism.endingPage2421
prism.issueIdentifier11
prism.publicationNameGenetics in Medicine
prism.startingPage2413
prism.volume21
dc.identifier.doi10.17863/CAM.57818
dcterms.dateAccepted2019-05-15
rioxxterms.versionofrecord10.1038/s41436-019-0554-6
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.contributor.orcidLove-Nichols, Jamie A. [0000-0003-4928-4078]
dc.contributor.orcidLedbetter, David H. [0000-0001-8934-4210]
dc.contributor.orcidScherer, Stephen W. [0000-0002-8326-1999]
dc.contributor.orcidSahin, Mustafa [0000-0001-7044-2953]
dc.contributor.orcidMiller, David T. [0000-0003-1060-1945]
dc.identifier.eissn1530-0366
pubs.funder-project-idWade Family Foundation (N/A)


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record